One Biosciences Announces €15 Million Series A Financing to Advance Clinical Single Cell Profiling

Hedi Ben Brahim, CEO of One Biosciences, said: "This funding enables us to translate our breakthrough single-cell technology into real-time insights that could directly inform physician decision-making, improve patient care, and accelerate drug development. The extraordinary support we have received from this group of leading global investors reinforces our conviction and fast-tracks our route to market." Hedi Ben Brahim, CEO of One Biosciences, said:   "This funding enables us to translate...

PARIS, 17/07/2025 (informazione.news - comunicati stampa - salute e benessere)

 

  :

One Biosciences, founded by Dr. Céline Vallot, Curie Institute and Home Biosciences in 2020, is an AI driven single cell transcriptomic oncology solutions company that is pioneering clinical grade single-cell tumor transcriptomic profiling. We aim to help clinicians select optimal treatments for their patients by decoding tumor heterogeneity from standard clinical samples, while enabling pharmaceutical companies to improve clinical trial outcomes. One Biosciences has partnerships with Curie Institute, Gustave Roussy Institute and AP-HP and is supported by Medicen, PSCC and Matwin. The company is financed by Bpifrance, Région Ile de France, France 2030, Redmile Group Blast, Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures and Kima Ventures.

For more information, visit: www.onebiosciences.fr

View original content:https://www.prnewswire.co.uk/news-releases/one-biosciences-announces-15-million-series-a-financing-to-advance-clinical-single-cell-profiling-302507084.html